Subscribe

Stemtech Corporation (STEK)

USD0.00 +0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address 10370 USA Today Way 33025
Naples, FL, US
CEO Charles S. Arnold
Website stemtech.com
IPO 2021-11-26
CIK 1511820 ISIN US85859W1027

Explore sections of this company profile

Description

Stemtech Corporation is a pioneering company specializing in stem cell nutrition. It formulates scientifically-backed products designed to optimize the body's intrinsic stem cell physiology. With a market presence spanning the Americas, Latin America, and Asia, its offerings are engineered to bolster the natural functions of the body's stem cells. These solutions achieve this by stimulating the release of more stem cells, facilitating their efficient circulation through the bloodstream, and guiding their migration into various tissues. This process enables the stem cells to perform their continuous regenerative and repair tasks, crucial for maintaining optimal health and vitality. The company's comprehensive portfolio of dietary supplements includes prominent brands such as RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze. Stemtech Corporation's operations are headquartered in Miramar, Florida.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
41M
Beta
2.52
Float Shares
103.06M
Free Float %
70.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +0.00% -33.33% -33.33% -88.89% -75.00% -99.45% -99.65% -99.99% -99.99% -99.99%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.00
Quality scores
Altman Z-Score
-21.16
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -43.1% Q4'25: -65.1% (vs Q4'24)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +37.1% ★ Q4'25: +100.0% (vs Q4'24)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +112.2% Q4'25: +27.7% (vs Q4'24)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +0.0% Q4'25: +0.0% (vs Q4'24)
  • ✓
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    — Q4'25: +0.0% (vs Q4'24)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +43.1% Q4'25: +43.1% (vs Q4'24)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    -1.03× Q4'25: -0.71× (vs Q4'24)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (3.09) × ERP
WACC = 1% × Ke + 99% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-28 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-27 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-26 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-22 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-21 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-19 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-18 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-15 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-14 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-13 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-12 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-11 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-08 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-07 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-06 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-05 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-04 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-05-01 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-30 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-29 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-28 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-27 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-24 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-23 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-22 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-21 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-20 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-17 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5
2026-04-16 C 2/5 1/5 5/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-539.7K
OE per share TTM
0.00
Owner's Yield
-1,589.10%
Maintenance CapEx ratio
351.83%
Maint CapEx / Avg PPE
2.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 KAPLAN 3.14M 6.86% 3.14M — — — IN Florida 2022-09-07 ↗

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
1.25M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,254,818
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2025-06-23 KAPLAN BENJAMIN NATHANIEL Director S-Sale D Common Stock 1,000,000 0.03 30.0K 1,198,905 I ↗
2024-07-26 ARNOLD CHARLES STUART Director P-Purchase A COMMON - CREST VENTURES LLC 25,000 0.05 1.3K 1,790,090 — ↗
2024-04-19 Mindshare Holdings, Inc. Other S-Sale D Common Stock 25,000 0.06 1.6K 2,433,399 — ↗
2023-08-08 Green Darryl V Director A-Award A COMMON 1,254,818 0.05 62.7K 3,963,930 — ↗
2023-06-12 Green Darryl V Director A-Award A Common Stock 2,408,818 0.05 120.4K 2,709,112 — ↗
2023-06-12 ARNOLD CHARLES STUART Director A-Award A COMMON 8,333,333 0.05 416.7K 15,474,926 — ↗

Executive team

Top executives
Shares Outstanding
146.18M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2026-05-29 10-K ↗
2026-05-14 NT 10-Q/A ↗
2026-05-14 NT 10-Q ↗
2026-03-31 NT 10-K ↗
2025-11-19 10-Q ↗
2025-11-14 NT 10-Q ↗
2025-08-19 10-Q ↗
2025-08-14 NT 10-Q ↗
2025-07-17 10-Q ↗
2025-06-30 10-K ↗

Executive team

NameTitleCompensationGender
Charles S. Arnold Chief Executive Officer & Director 250.0K male
John W. Meyer President, Chief Operating Officer & Director 120.0K male
Shrilakshmi Vadlapatla Chief Financial Officer 55.6K female
David E. Price Secretary — male
Lizette Leos Chief Scientific Officer & Member of Life Sciences Advisory Board — —
Tufan Obuz Chief Administrative Officer — male
ESG Rating
B
DRUG MANUFACTURERS - SPECIALTY & GENERIC
2023
E (Environmental)
74.5 / 66.0
Company / Sector avg.
S (Social)
71.4 / 70.0
Company / Sector avg.
G (Governance)
69.9 / 66.6
Company / Sector avg.
ESG Total
71.9 / 67.5
Company / Sector avg.
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic